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y 27, 2013.he goal of this study was to develop a low-energy, implantable device–based multistage electrotherapy (MSE) to
terminate atrial ﬁbrillation (AF).Background Previous attempts to perform cardioversion of AF by using an implantable device were limited by the pain caused by
use of a high-energy single biphasic shock (BPS).Methods Transvenous leads were implanted into the right atrium (RA), coronary sinus, and left pulmonary artery of 14 dogs.
Self-sustaining AF was induced by 6  2 weeks of high-rate RA pacing. Atrial deﬁbrillation thresholds of standard
versus experimental electrotherapies were measured in vivo and studied by using optical imaging in vitro.Results The mean AF cycle length (CL) in vivo was 112 21 ms (534 beats/min). The impedances of the RA–left pulmonary
artery andRA–coronary sinus shock vectorswere similar (12111U vs. 1269U; p¼0.27). BPS required1.480.91
J (165 34 V) to terminate AF. In contrast, MSE terminated AF with signiﬁcantly less energy (0.16  0.16 J; p <
0.001) and signiﬁcantly lower peak voltage (31.1 19.3 V; p< 0.001). In vitro optical imaging studies found that AF
was maintained by localized foci originating from pulmonary vein–left atrium interfaces. MSE Stage 1 shocks
temporarily disrupted localized foci; MSE Stage 2 entrainment shocks continued to silence the localized foci driving
AF; and MSE Stage 3 pacing stimuli enabled consistent RA–left atrium activation until sinus rhythm was restored.Conclusions Low-energy MSE signiﬁcantly reduced the atrial deﬁbrillation thresholds compared with BPS in a canine model of AF.
MSE may enable painless, device-based AF therapy. (J Am Coll Cardiol 2014;63:40–8) ª 2014 by the American
College of Cardiology FoundationAtrial ﬁbrillation (AF) is the most common tachyarrhythmia
worldwide, and the number of Americans afﬂicted with AF
is projected to reach 12 million by 2050 (1). Although
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13; revised manuscript received July 24, 2013,complications, and recurrence after a single catheter ablation
procedure is relatively high (2). Cardioversion of AF by
using high-voltage external biphasic shocks remains
a mainstay of therapy. However, external cardioversion
incurs costly anesthesia and hospitalization expenses; treat-
ment fees associated with AF are estimated to cost Medicare
more than $15.7 billion annually (3).See page 49Internal atrial cardioversion requires signiﬁcantly less
energy than external cardioversion (4). Thus, it may be
possible to cardiovert AF internally below the pain
threshold, which is variably reported to be between 0.1 J and
1 J (5,6). These considerations prompted efforts to design an
implantable device that converts AF to sinus rhythm safely
and painlessly, thereby ameliorating symptoms and poten-
tially reducing the likelihood of atrial remodeling (7).
Abbreviations
and Acronyms
ASET = atrial shock
excitation threshold
BPS = single biphasic shock
CS = coronary sinus
DFT = deﬁbrillation threshold
HRP = high-rate pacing
LA = left atrium
LPA = left pulmonary artery
MSE = multistage
electrotherapy
OAP = optical action
potential
PV = pulmonary vein
RA = right atrium
RAA = right atrial appendage
VSET = ventricular shock
excitation threshold
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41Historically, these attempts failed largely due to the fact that
the atrial deﬁbrillation threshold (DFT) of a single biphasic
shock (BPS) remains above the pain threshold (8–11).
We, therefore, developed an electrotherapy protocol
arising from the demonstrated phase dependence of the tissue
response to shocks (12). This therapy was developed from the
initial discovery that there is a shock strength phase depen-
dence for successful unpinning of atrial and ventricular
tachyarrhythmias (13,14) and the notion that multiple pulses
increase the probability of delivering a low-voltage shock
during the optimal temporal window (12,15). From these
initial studies, we hypothesized that a further decrease in peak
voltage could be achieved if the multiple pulses were followed
by antirepinning phases to prevent the reinitiation of AF.We
previously tested several stages of multistage electrotherapy
(MSE) and found that the 3-stage therapy resulted in the
lowest atrial DFT (16). Therefore, our novel electrotherapy
consists of 3 stages of successively decreasing energy levels,
which we refer to as MSE (16,17). In the present study, we
prospectively compared MSE with BPS to establish the
deﬁbrillation threshold in a canine in vivo model of
tachypacing-induced AF, delivered through chronically-
implanted transvenous leads. Subsequently, we investigated
the mechanism by which MSE terminates AF by using
optical mapping.Methods
Surgical procedures. All animal procedures were per-
formed in accordance with the position of the American
Heart Association on the use of research animals (updated in
1985) and were approved by the Washington University
Animal Studies Committee. Mongrel dogs (N ¼ 14)
weighing 20 to 25 kg were anesthetized, and pacing/deﬁ-
brillation leads (Medtronic, Inc., Minneapolis, Minnesota)
were introduced from the right internal jugular vein with
ﬂuoroscopic guidance. In all dogs, a pacing lead (model
number 5096; Medtronic, Inc.) was implanted into the right
atrial appendage (RAA), and deﬁbrillation leads were
implanted into the RAA (model number 6935; Medtronic,
Inc.), left pulmonary artery (LPA), and coronary sinus (CS)
(model number 6937A; Medtronic, Inc.). The CS of canine
hearts often tapers abruptly, preventing implantation of
a lead in the distal CS. The inferior branch of the LPA runs
adjacent to the lateral CS and was therefore used to
anatomically approximate the clinical distal CS implantation
site (Fig. 1A).
The pacing lead was connected to an implanted high-rate
pacing (HRP) device (Medtronic, Inc.) programmed with
custom software. Deﬁbrillation leads were connected to
custom subcutaneous access ports (Evergreen Medical
Technologies, Minneapolis, Minnesota). Figure 1 shows
ﬂuoroscopic and schematic images depicting subcutaneous
access ports and lead positions.
Each animal underwent a complex experimental protocol,
including the surgical implant and subsequent deﬁbrillationstudies. A timeline illustrating
the experimental sequence of
events is shown in Figure 1C.
During survival deﬁbrilla-
tion studies, animals were re-
anesthetized, and the subcutaneous
access ports were accessed trans-
cutaneously by using needle
electrodes (Evergreen Medical
Technologies) under ﬂuoro-
scopic guidance. Blood pressure,
electrolyte levels, and arterial
oxygen saturation were moni-
tored continuously.
HRP-induced self-sustaining AF.
The HRP at 400 beats/min
began 1 week after implantation
from the RAA pacing lead at
twice the atrial capture threshold.
Digoxin (Jerome Stevens Phar-
maceuticals, Inc., Bohemia, New
York) was administered orally once daily to limit the
ventricular rate during HRP and AF. Device and rhythm
checks were performed weekly to determine AF induction.
AF was deﬁned as an irregular fast atrial rhythm occurring at
a cycle length (CL) of <150 ms (>400 beats/min). For this
study, AF was deﬁned as self-sustained AF lasting>30 min
during interrogation. Once this arrhythmia was observed,
the animal was rechecked 1 week later to determine if AF
persisted for 1 week. If AF was present, survival deﬁbril-
lation studies were performed. After the ﬁnal in vivo deﬁ-
brillation study, hearts were explanted for the in vitro
mechanism investigations.
Atrial and ventricular shock excitation thresholds.
Animals in AF at the start of the deﬁbrillation study
underwent cardioversion by using a 10- to 30-J external
shock to enable accurate measurement of the atrial shock
excitation threshold (ASET) and the ventricular shock
excitation threshold (VSET) during sinus rhythm. ASET
and VSET, deﬁned as the minimum energy by which a
10-ms monophasic square wave shock excited the atrium or
ventricle, respectively, were measured for each deﬁbrilla-
tion vector (RA-CS and RA-LPA) at the start of each
in vivo deﬁbrillation study during the diastolic interval
during sinus rhythm. Shock excitation thresholds were
determined by evaluation of surface and endocardial
electrograms.
Electrotherapies tested. The electrotherapies tested are
shown in Figure 2A. BPS (Fig. 2A, left panel) triggered to
the ventricular R-wave (6/4 ms duration and a 2:1 ratio of
the leading-edge voltages of the 2 phases) was compared
with MSE (Fig. 2A, right panel). Before each application of
MSE, AF was analyzed using a fast Fourier transform
algorithm to determine the dominant frequency, which was
expressed as a CL. Once the AF CL was determined, the
MSE was delivered in 3 stages. In Stage 1, 2 biphasic shocks
Figure 1 Chronically Implanted Lead Positions and Experimental Timeline
(A) Fluoroscopic images of the anatomic positions of chronically-implanted transvenous leads and subcutaneous (SC) access ports from left lateral (left panel) and left anterior
oblique (right panel) views. (B) Schematic depiction of lead positions. Shocks were delivered from the right atrium (RA) coil to the left pulmonary artery (LPA) coil or the RA coil to
the coronary sinus (CS) coil. (C) Experimental timeline showing model development and approximate times of deﬁbrillation (deﬁb) studies. AF ¼ atrial ﬁbrillation; HRP ¼ high
rate pacing; LA ¼ left atrium; LV ¼ left ventricle; PT ¼ pulmonary trunk; RV ¼ right ventricle; SVC ¼ superior vena cava; Wk ¼ week.
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42(6/4 ms duration and 2:1 ratio of the leading-edge voltages
of the 2 phases) were delivered within 1 length of the AF
CL (time between the 2 shocks was equal to 50% of AF CL)
and were triggered to the R-wave. After a 50-ms delay,
Stage 2 of MSE was delivered and consisted of 6 mono-
phasic shocks (each 10 ms in duration) delivered at an
interval of 88% of the AF CL and at a voltage that is 60% of
the VSET. After another 50-ms delay, Stage 3 of MSE was
delivered; it consisted of pacing from the RAA lead at an
interval of 88% of the AF CL, delivered at twice the atrial
pacing threshold. Importantly, the only change in MSE after
an unsuccessful cardioversion was an increase in the Stage 1
peak leading-edge voltage (i.e., the peak voltage of the 2
biphasic shocks delivered within a single AF CL). Stage 2
shocks were ﬁxed for each animal based on VSET, whereas
Stage 3 pacing remained ﬁxed for a given animal based on
the atrial pacing capture threshold; once established at the
outset of the in vivo cardioversion studies, Stage 2 and 3
amplitudes did not vary.Similarly, the only change to the BPS electrotherapy after
an unsuccessful cardioversion was an increase in the peak
leading-edge voltage.
Deﬁbrillation protocol for in vivo survival studies. AF
was induced by 50-Hz burst pacing from the RAA pacing
lead at twice the atrial pacing threshold. The mean AF CL
was determined for AF lasting >5 min by using a real-time
fast Fourier transform algorithm. Atrial DFTs of both
electrotherapies were measured by using a randomized,
voltage-regulated, step-up protocol. After each induction of
AF, either BPS or MSE was randomly chosen. Once
chosen, the speciﬁed therapy was applied. For BPS, the peak
leading-edge voltage was applied initially at twice the ASET
and then doubled until successful cardioversion. For MSE,
the peak leading-edge voltage of Stage 1 biphasic shocks
was initially applied at twice the ASET and then followed
by ﬁxed voltages and pacing outputs for Stage 2 and
Stage 3, respectively. After unsuccessful cardioversion by
MSE, only the peak leading-edge voltage of Stage 1
Figure 2 In Vivo Cardioversion of AF by BPS Versus MSE
(A) Deﬁbrillation therapies tested. The left panel shows a single truncated exponential single biphasic shock (BPS). The right panel shows the multistage electrotherapy (MSE).
Therapy in red was delivered through deﬁbrillation coils, whereas the blue stage was delivered through the right atrial appendage pacing lead. (B) Surface electrogram and
deﬁbrillation threshold (DFT) of the sample in vivo atrial ﬁbrillation (AF) terminations by using BPS and MSE. (C and D) Summary of in vivo atrial DFTs (n ¼ 8) for BPS versus MSE.
The peak shock voltage represents the maximum leading-edge voltage required for cardioversion by BPS or BPS delivered in Stage 1 of MSE. The total energy represents the
sum of the energy of all stages of each therapy. Values are mean  SE in C and median þ quartiles in D.
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43(2 biphasic shocks) was doubled, and MSE was reapplied
until successful cardioversion. Successful cardioversion was
deﬁned as the restoration of sinus rhythm within 10 s of the
start of therapy application. To prevent time-dependent
carryover effects on the measurement of atrial DFT,
a 5-min rest period was observed after each successful car-
dioversion (16). Electrotherapies were delivered from
computer-controlled, regulated power supplies (BOP 100-4M,
Kepco, Inc., Flushing, New York). Impedances were
calculated by using a current probe (A622, Tektronix, Inc.,
Beaverton, Oregon) during the shock excitation thresholdtesting shocks. At the conclusion of each survival deﬁbrilla-
tion study, HRP was resumed after a 24-h recovery period.
Optical mapping of MSE in vitro. After the ﬁnal deﬁ-
brillation study, the heart was perfused in a retrograde fashion
through the aorta with heparinized cardioplegic solution and
explanted. Ventricles were removed, and the endocardial
surfaces of the atria and pulmonary veins (PVs) were exposed.
The right and left coronary arteries were perfused with
oxygenated Tyrode’s solution, Blebbistatin (R&D Systems,
Ellisville, Missouri), to reduce motion artifact, and a ﬂuores-
cent, voltage-sensitive dye (Di-4 ANEPPS, Molecular
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44Probes, Eugene, Oregon) to enable recording of optical action
potentials. Optical action potentials (OAPs) were acquired by
using a CMOS camera (SciMedia USA Ltd., Costa Mesa,
California) with high spatial (100 100 pixels) and temporal
(1,000 frames/s) resolution from a 2.5 2.5 cm ﬁeld of view.
Two silver/silver chloride–sensing electrodes were placed
lateral to the LA and RA for constant monitoring. A bipolar
RAA electrode was used for pacing and induction of AF by
50-Hz burst pacing. Electrotherapies were delivered from 2
parallel mesh electrodes placed lateral to the LA and RA 10
cm apart. Optical mapping was performed as described
previously (18). To capture the arrhythmia, application of
therapy, and the immediate tissue response, 8-s optical ﬁles
were recorded for each trial. The optical ﬁles were analyzed to
determine the spatiotemporal characteristics of the induced
arrhythmias. This method included the local dominant
frequencies and the regularity index, which is a signal-
processing measure of the stability of the periodicity of the
arrhythmia at each location (19). It is calculated as the ratio of
the power in a 1-Hz band centered on the dominant frequency
compared with the total power across all frequencies up to
200 Hz. In addition, the sequential tissue response to each
stage of therapywas analyzed by observing the advancement of
the wave front. Both OAP and phase were used in this anal-
ysis, as previously described (20).
Statistical analysis. The deﬁbrillation protocol randomized
the sequence of electrotherapies to prevent the confounding
effects of treatments with respect to time. Recovery periods
were observed after each AF termination to prevent carryover
effects. Paired Student t tests were used to compare ASET
with VSET for a given shock, and the Mann-Whitney test
was used to compare impedances of the 2 vectors by using
Prism 5.0c (GraphPad Software, La Jolla, California). DFT
comparisons were analyzedwith a linearmixed random effects
model with animal identiﬁcation as a random effect and the
period between treatments as a ﬁxed effect. Animal identiﬁ-
cation  therapy was also analyzed as a random effect to test
for interactions. Estimates were calculated with the MIXEDFigure 3 DF Analysis of AF In Vitro
(A) In vitro tissue preparation of the endocardial canine atrium used to record optical acti
dominant frequency (DF) during the sample in vitro AF episode. Example OAP traces during
close to 1 represents a highly stable region with a narrow power distribution around DF. Re
free atrial wall. LCA ¼ left coronary artery; RCA ¼ right coronary artery; other abbreviationprocedure in SAS version 9.2 (SAS Institute, Inc., Cary,
North Carolina). Results are reported as mean  SD. A
p value of 0.05 was considered signiﬁcant.Results
Chronic HRP model of AF. Of the 14 canines implanted,
4 were euthanized before DFT testing was performed due to
systemic bacterial infection. The remaining 10 dogs devel-
oped self-sustained AF. Eight dogs were used for in vivo
survival deﬁbrillation studies and 7 were used for terminal
optical mapping studies (5 canines were used for both
studies). The mean duration of HRP required to induce
self-sustaining AF was 6  2 weeks. The mean AF CL
in vivo was 112  21 ms. For the RA-LPA vector, the mean
ASET was 4.1  2.9 V, and the mean VSET was 8.1  3.2
V (p < 0.001). For the RA-CS vector, the mean ASET was
3.3  0.5 V, and the mean VSET was 8.0  3.2 V
(p < 0.001). The impedances of the RA-LPA and RA-CS
vectors were not statistically different (121  11 U vs. 126 
9 U, respectively; p ¼ 0.27).
In vivo atrial cardioversion studies. A total of 32 in vivo
deﬁbrillation studies were performed in 8 dogs. A total of 123
episodes of sustained AF were successfully converted to sinus
rhythm, yielding an average of 3.8 cardioversions per study.
Sample terminations by BPS and MSE in a single survival
deﬁbrillation study are shown in Figure 2B. In this example,
the atrialDFTofBPSwas 170V (1.65 J) comparedwith 2.5V
(0.02 J) for MSE. Average results (8 dogs) are shown in
Figure 2C. The mean DFT of MSE was signiﬁcantly lower
compared with that of BPS in terms of total energy (0.16 
0.16 J vs. 1.48  0.91 J, respectively; p < 0.001) and peak
shock voltage (31.1  19.3 V vs. 165  34 V, respectively;
p< 0.001). Importantly, these results demonstrate that atrial
DFT can be effectively lowered by using commercially
available transvenous implantable leads placed in RA and CS.
In vitro organization of AF. The hearts of 7 dogs with
self-sustaining AF induced by HRP were explanted foron potentials (OAPs). Field of view is shown by the white box. (B) Spatial map of the
AF are shown from the selected regions. (C) Spatial pattern of regularity index. A value
gions close to the pulmonary veins (PVs) show increased stability compared with the
s as in Figure 1.
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45mechanistic studies. Due to denervation, some hearts
required the perfusion of acetylcholine to induce sustained
AF in vitro. A representative in vitro AF episode is shown in
Figure 3. The optical imaging ﬁeld of view is shown in
Figure 3A. Notably, this view incorporated the interfaces
between the PVs and the left atrium (LA). Figure 3B
illustrates the spatial relationship of the dominant frequen-
cies across the ﬁeld of view (frequency resolution of
0.25 Hz). Sample optical recordings are shown from the
highest dominant frequency locations. Interestingly, the
highest frequency components (in this heart) originated in
the right and left superior PVs. High-frequency drivers of
AF were seen at the PVs or LA-PV interfaces in all canine
hearts imaged in vitro (data not shown). Figure 3C shows an
analysis of the regularity index; the highest and most stable
frequencies were located at the PV or PV-LA interfaces.
Taken together, these observations suggest that the PV and
LA-PV interfaces incorporate relatively independent, stable,
and high-frequency AF drivers in this model.
Optical mapping of cardioversion of AF by MSE. The
in vitro studies conﬁrmed the DFT superiority of MSE
compared with BPS. The atrial DFT of MSE observed inFigure 4 Optical Mapping of Successful Termination of AF by MSE
The white box in the top left panel shows the ﬁeld of view. Activation maps during a repre
(C) Stage 1 shocks. (D to H) Stage 2 shocks. (I to K) select Stage 3 pulses. (L) Restothese studies (n ¼ 7) was 3.88  0.9 V/cm (1.2  0.2 J)
versus 9.40  1.34 V/cm (3.4  0.4 J) for BPS (p < 0.05).
To illustrate a possible mechanism of successfully decreasing
the DFT with MSE, we took a 2-fold approach. First, we
analyzed the spatial sequence of activation after each stage of
a representative, successfully delivered MSE trial (Fig. 4).
The spatial evolution of the tissue response after the appli-
cation of MSE was then contrasted between an example of
successful MSE application (with a peak voltage of 7 V/cm
in this case) and an unsuccessful application (5 V/cm) from
the same animal (Fig. 5).
During this example of an AF episode, 2 initiating
localized foci were noted, the ﬁrst coming from the left
superior PV (Fig. 4A) and another from the right superior
PV (Fig. 4B). Figure 4C shows the activation pattern when
Stage 1 shocks were delivered, causing fast activation of the
LA in w60 ms, compared with w90 ms during AF. The
ﬁrst shock of Stage 2 was delivered during the atrial
refractory period and thus failed to initiate a new action
potential. The remaining 5 Stage 2 shocks (Figs. 4D to 4H)
activated the LA in a left-to-right activation pattern.
Successive Stage 2 shocks resulted in increasingly regularizedsentative successful application of MSE with a peak voltage of 7 V/cm. (A and B) AF.
red sinus rhythm. Abbreviations as in Figure 2.
Figure 5 Phase Analysis of Successful and Unsuccessful Termination of AF by MSE
Spatial maps of phase immediately after each intervention of MSE in sample successful and unsuccessful terminations. (A) Successful termination with a peak shock strength
of 7 V/cm displayed with representative optical trace from middle of the ﬁeld of view (orange trace). The panels show the evolution of phase during therapy application,
beginning with an AF example, then proceeding to Stage 1 shocks 1 and 2; Stage 2 shocks 2, 4, and 6; and ﬁrst stimulus of Stage 3. The middle left panel in A shows
a representative optical action potential with the deﬁnition of phase. (B) Unsuccessful termination with a peak shock strength of 5 V/cm displayed with representative optical
trace from the middle of the ﬁeld of view (blue trace). Panels show evolution of failed response to therapy, starting from an AF example, then progressing to Stage 1 shocks
1 and 2; Stage 2 shocks 2 and 4 through 6; and ﬁrst stimulus of Stage 3. Abbreviations as in Figure 2.
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46activation patterns (compare Fig. 4D with Fig. 4H). Finally,
Stage 3 stimuli activated the atria in a pattern nearly iden-
tical to that seen during sinus rhythm, in which the wave
front spread from the RA to the LA via Bachmann’s bundle.In Figure 5, each map charts the phase distribution
immediately after each intervention in MSE. The top left
panel shows a representative OAP with the color distribu-
tion of phase. Because AF is a complex, multidriver
JACC Vol. 63, No. 1, 2014 Janardhan et al.
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47arrhythmia, the 2 shocks in Stage 1 must disrupt these
drivers and spatially homogenize the potential. Because this
process is both time- and peak voltage–sensitive, having 2
shocks increases the likelihood of successfully targeting the
optimal delivery time. Both shocks combine to incrementally
homogenize the tissue in Figure 5A, whereas in Figure 5B,
the ﬁrst shock fails and the second leaves some regions in
various phases. In the successful case, Stage 2 shocks then
sequentially capture more of the tissue, restraining the source
of the arrhythmia from recurring. Stage 3 can clearly drive
the whole tissue in the successful case and prime the tissue
for sinus rhythm, which resumes w700 ms after the last
application of MSE Stage 3. Stage 2 fails in the unsuccessful
case; as a result, the focal drivers of the arrhythmia reemerge
before the end of Stage 2. Therefore, MSE succeeds at
a lower peak voltage because Stage 1 can reset the tissue,
which allows the Stage 2 shocks to slowly increase the
amount of tissue that is captured by the applied shocks,
preventing any critical points that may result from the virtual
electrode polarization (VEP) of the initial shocks or the
original drivers to reinitiate the arrhythmia. This action thus
prepares the atria for the pacing spikes of Stage 3 to reset the
repolarization pathway.
Discussion
Our results show that MSE signiﬁcantly reduced the DFT
compared with BPS in an in vivo canine model of
tachypacing-induced, self-sustaining AF and in vitro atrial
preparations. In vivo, MSE signiﬁcantly reduced the total
energy (0.16  0.16 J vs. 1.48  0.91 J) and the peak shock
voltage (31.1  19.3 V vs. 165  34 V) compared with BPS.
Electrocardiographic analysis of deﬁbrillation in vivo is
limited by low spatial resolution and saturation of the elec-
trogram during the application of shocks. Therefore, we
investigated the biophysical mechanism of cardioversion by
MSE using optical imaging in vitro, which is immune to
shock-induced artifacts (21). The optical imaging studies
found that MSE gradually eliminated the foci localized
around the PV-LA interfaces that sustain AF until sinus
rhythm was restored, as previously observed in therapy of
ventricular tachycardia (15).
Chronic high-rate atrial pacing model of AF. This study
used an animal model in which chronic atrial tachypacing
induces structural and electrical remodeling similar to that
observed in humans with AF (22–28). The similarities
suggest that this is a plausible model in which to study
cardioversion of AF, and they increase the likelihood that
the differences in atrial DFT between standard BPS and
experimental MSE observed in this canine model will
extend to humans (29,30). The degree of remodeling was
not characterized in this experiment, and variability may
exist between individual animals.
Termination mechanism. The high-resolution analysis of
deﬁbrillation during AF showed that MSE, over the course
of the multiple shock and pacing therapies, graduallyeliminates these localized foci until sinus rhythm is restored.
In past experiments on AF deﬁbrillation, we relied on the
secondary sources of excitation caused by the virtual elec-
trodes of higher-voltage shocks to self-direct the restoration
of sinus rhythm (12). However, in the case of MSE, the
Stage 2 shocks play this role after the Stage 1 shocks,
sequentially advancing more of the tissue and allowing the
Stage 3 pacing to reset the rhythm for the restoration of
sinus beats. This actively-controlled therapy allows for the
successful decrease in both peak voltage and total energy,
and it can be delivered from intravenously-deployed leads
placed in commonly used implantation sites (RA and CS).
Study limitations. The mechanistic conclusions drawn
from this study are limited to the interpretation of observed
potential and phase responses in several preparations and are
not extended to a quantiﬁed description. In addition, the
optical mapping results are limited by the fact that the intact
heart was dissected to image the endocardial surface of
the LA and PVs. It is possible that this process may have
disrupted the localized circuits of the intrinsic in vivo
arrhythmia. Also, during the in vitro studies, the energy was
delivered uniformly across the atria from 2 large electrodes
on the exterior of the tissue. This method is different from
the electrode orientation used during the in vivo studies.
Despite these limitations, MSE signiﬁcantly lowered the
atrial DFT both in vitro and in vivo compared with BPS.
Future studies will be performed to evaluate the probability
of success of the MSE treatment at the lower voltages and
to determine efﬁcacy. This investigation provides valuable
insight into the biophysical response to, and mechanism of,
MSE to restore sinus rhythm, and it demonstrates that
MSE achieved signiﬁcantly lower atrial DFTs than the
existing clinical standard (i.e., BPS).
Toward pain-free cardioversion of AF. Using BPS,
delivered from a transvenous atrial lead system similar to that
described in the present report, Lok et al. (6) found that
nonsedated patients in AF for >1 month tolerated shocks of
2.5  1.3 J, whereas Murgatroyd and Camm (31) reported
that patients required sedation for shocks >1.1 to 1.2 J.
Importantly, the mean DFT of MSE in the canine model
of tachypacing-induced AF used in our study was 0.16 J.
Using a chronically-implanted device, Wellens et al. (32)
reported that a 2.5- to 2.7-J biphasic shock delivered
from leads implanted in the RA and CS terminated 86.3%
of AF episodes. Thus, although future studies in humans
will be necessary, it is likely that the use of MSE in an
implantable, transvenous lead–based device will be signiﬁ-
cantly superior to previous devices that relied on BPS. If
VSET is found to be higher in humans, the energy of Stage
2 could be optimized at lower levels than 60% VSET.
Conclusions
This study used a rapid atrial pacing model of AF to
measure the atrial DFT of a standard BPS compared with
MSE for potential use in an implantable device–based atrial
Janardhan et al. JACC Vol. 63, No. 1, 2014
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48cardioverter. In vitro optical imaging studies indicated that
AF in this canine model was maintained by multiple, rapidly
ﬁring localized foci at the PV-LA interface. MSE gradually
eliminated these foci by using a sequence of shocks followed
by pacing. In vivo, MSE terminated AF with signiﬁcantly
lower energy and voltage compared with BPS. The mean
atrial DFT of MSE in this study was below the shock
strength that has been reported to cause pain in humans
during in vivo testing, suggesting that device-based, pain-
free atrial deﬁbrillation may be achievable.
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